Ocean Biomedical, Partner Virion Therapeutics in Phase 1b forl Immunotherapy for Chronic Hepatitis B

 Ocean Biomedical, Inc. (NASDAQ:OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today announced that its joint venture partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection. VRON-0200, a first-in-class treatment, using one of Virion’s proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient’s own immune response. This novel mechanism of action may help overcome one of the key problems faced in treating chronic HBV—immune exhaustion. The international, first-in-human VRON-0200 Phase 1b study is currently enrolling patients in Hong Kong and New Zealand, with additional sites planned in the United States. Initial clinical data from this study are expected in early 2024.

https://www.biospace.com/article/releases/ocean-biomedical-nasdaq-ocea-announces-first-patients-dosed-by-joint-venture-partner-virion-therapeutics-in-phase-1b-study-of-novel-immunotherapy-for-chronic-hepatitis-b-virus-infection/